Multiple Dose Study of MK-6024 in Healthy Japanese Participants

A Multiple-Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-6024 in Healthy Japanese Participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210703

Enrollment

Registered

2022-03-26

Start date

2022-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic steatohepatitis

Interventions

The participants will receive multiple SC doses of MK-6024 or matching placebo for total 16 weeks (MK-6024 2.4, 5, 7.4 and 10 mg, or placebo for every 4 week).

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy male aged 20 to 65 years old with BMI 23 to 40 kg/m2

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
AEs and AEs leading to discontinuation	—

Secondary

Measure	Time frame
Following serum PK parameters -Following 4th, 8th, 12th and last (16th) doses: Tmax, Cmax, AUC0-tau -Following 16th dose: t1/2, CL/F, Vz/F -Following 3rd, 4th, 7th, 8th, 11th to 16th doses: Ctrough	—

Contacts

Public ContactMSDJRCT inquiry mailbox

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026